Evidence map›Paper›PMID 34275068›Full record

ReviewAnnals of nuclear medicine2021

Transthyretin cardiac amyloidosis: a review of the nuclear imaging findings with emphasis on the radiotracers mechanisms.

Teodor M Ionescu, Wael Jalloul, Cati R Stolniceanu, Roxana Iacob, Laura P Grecu, Ana-Maria Stătescu, Irena Grierosu, Mihai Guțu, Adrian Gavrilescu, Crișu Daniela and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Teodor M IonescuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania. teodor_y_2005@yahoo.com.ORCID http://orcid.org/0000-0001-8453-9908
Wael JalloulNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Cati R StolniceanuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Roxana IacobNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Laura P GrecuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Ana-Maria StătescuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Irena GrierosuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Mihai GuțuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Adrian GavrilescuCardiology Department, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Crișu DanielaCardiology Department, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Antoniu PetrișCardiology Department, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Manuela CiocoiuUniversity of Medicine and Pharmacy U.M.F "Grigore T. Popa", Iași, Romania.
Cristina UngureanuEndocrinology Department, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Cipriana ȘtefănescuNuclear Medicine Laboratory, County Emergency Hospital "Sf. Spiridon", Iași, Romania.
Grigore T. Popa University of Medicine and Pharmacy · ROSpitalul Clinic Judeţean de Urgenţe "Sf. Spiridon" Iaşi · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac amyloidosis is a protein deposition disease characterized by the infiltration of the myocardium and coronary arteries resulting in a progressive thickening of both ventricles, interatrial septum and atrioventricular valves, eventually leading to organ failure. It is a disease hard to diagnose, due to the lack of diagnostic investigations. However, development of new and more accurate examinations is undergoing. Endomyocardial biopsy is the gold standard investigation for this disease, but it has its limitations (invasive and not widely available). Other investigations may be able to detect the presence of cardiac amyloidosis but cannot specify the type involved. To that end, nuclear medicine through bone scanning offers a simple, non-invasive solution to detect, differentiate and diagnose transthyretin cardiac amyloidosis (ATTR) from other types of cardiac amyloidosis. In order to demonstrate the importance of bone scanning we will present a few methods of image processing based on literature and a personalized method, followed by a few important examples of positive cases. The aim of this review was to present the current methods of ATTR detection with emphasis on nuclear medicine bone scanning and its important place in the decision algorithm of the cardiologist for a personalized approach to this pathology.

Indexed as

Amyloid Neuropathies, FamilialAmyloidosisBone and BonesCardiomyopathiesHumansPrealbuminRadioactive TracersRadionuclide ImagingPrealbuminRadioactive TracersBone scanCardiac amyloidosisPersonalized medicineTransthyretin cardiac amyloidosisTransthyretin cardiac amyloidosis detection methods

Identifiers

PMID34275068
OpenAlexW3185627714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.